Table 2 Results – Epidemiology
From: Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review
Author (year) | Tool to Measure Fatigue; Cut-off Value Used | Outcome(s) | n evaluated for fatigue | Fatigue (%) |
|---|---|---|---|---|
Adult | ||||
 Alvarenga-Filho (2015) | MFIS; ≥ 38 | Prevalence | NR | 35.0 |
 Anens (2014) | FSS; ≥ 4 | Prevalence | 285 | 61.7 |
 Battaglia (2017) | VAS (0–10); NR | Prevalence | 997 | 96.0 |
 Calabrese (2017) | VAS (0–10); NR | Prevalence | 703 | 93.0 |
 Fiest (2016) | D-FIS; ≥ 5.0 | Prevalence, Incidence | 943 | 78.0 |
 Flachenecker (2017) | VAS (0–10); NR | Prevalence | 5233 | 96.0 |
 Fricska-Nagy (2016) | FIS; NR | Prevalence | 402 | 62.4 |
 Hadgkiss (2013) | FSS; ≥ 4 | Prevalence | 2143 | 65.7 |
 Havrdova (2017) | VAS (0–10); NR | Prevalence | 727 | 92.0 |
 Kratz (2016) | 11-point scale; Occurrence: >  0, Severe: >  6 | Prevalence | 180 | 88.0 |
 Labuz-Roszak (2012) | FSS; >  36 a | Prevalence | 122 | 61.5 |
 Larnaout (2018) b | FSS; > 4, MFIS; >  38 c | Prevalence | NR | 60.0 |
 Lebrun-Frenay (2017) | VAS (0–10); NR | Prevalence | 454 | 95.0 |
 Oreja-Guevara (2017) | VAS (0–10); NR | Prevalence | 446 | 92.0 |
 Pentek (2017) | VAS (0–10); NR | Prevalence | 508 | 94.0 |
 Pokryszko-Dragan (2016) | FSS; ≥ 4 | Prevalence | 44 | 18.2 |
 Reilly (2017) | FSS; ≥ 4 | Prevalence | 2079 | 65.6 |
 Rooney (2019) | FSS; ≥ 5 | Prevalence | 412 | 68.7 |
 Runia (2015) | FSS; ≥ 5 | Prevalence | 127 | 46.5 |
 Selmaj (2017) | VAS (0–10); NR | Prevalence | 408 | 97.0 |
 Thompson (2017) | VAS (0–10); NR | Prevalence | 769 | 96.0 |
 Uitdehaag (2017) | VAS (0–10); NR | Prevalence | 381 | 96.0 |
 van der Vuurst de Vries (2017) | FSS; ≥ 5 | Prevalence | NR | 35.3 |
 von Bismarck (2018) | FSMC; At least mild fatigue (>  42 Pt.) | Prevalence | 1069 | 36.5 |
 Weiland (2015) | FSS; ≥4 | Prevalence | 2138 | 65.6 |
 Weiland (2019) d | FSS; ≥ 4 | Prevalence, Longitudinal | 1268 1268 509 | 56.0 62.5 53.8 |
 Wood (2013) | FSS; ≥ 5 | Prevalence | 192 | 53.7 |
Pediatric | ||||
 Florea (2019) | FSS; Moderate ≥3 | Prevalence | 23 | 43.0 |
 Goretti (2010) | FSS; ≥ 4 | Prevalence | 56 | 20.0 |
 Parrish (2013) | PedsQL Multidimensional Fatigue Scale; Total Fatigue ≥36 | Prevalence | 24 | 29.2 |
 van’s Gravesande (2019) b | PedsQL Multidimensional Fatigue Scale; Mildly impaired: score 1–2 SDs below healthy controls, severely impaired: score > 2 SDs below healthy controls | Prevalence | 106 | 40.6 |
Mixed or unknown age | ||||
 Garcia (2019) a, b, e | FSS; Persistent fatigue ≥28, NFI-MS/BR; persistent fatigue ≥30 | Prevalence, Longitudinal; Mixed age | 38 26 | FSS: 74.4, 54.0 NFI-MS/BR: 64.0, 47.0 |
 Kaya Aygunoglu (2015) | FSS; ≥4 | Prevalence | 120 | 70.0 |
 Razazian (2014) | FSS; ≥ 5 | Prevalence | 300 | 62.3 |
 Rupprecht (2018) b | MFIS; NR | Prevalence | NR | 45.0 |